By Lori Solomon HealthDay ReporterMONDAY, Aug. 11, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this ...

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years who weigh at least 45 kg.With this approval, AJOVY becomes ...

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

The calcitonin gene-related peptide (CGRP) blocker was approved for adults in 2018. Fremanezumab is the first CGRP antagonist ...

AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in ...